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Abstract
HPV DNA integration into the host genome is a characteristic but not an exclusive step during cervical carcinogenesis. It is
still a matter of debate whether viral integration contributes to the transformation process beyond ensuring the constitutive
expression of the viral oncogenes. There is mounting evidence for a non-random distribution of integration loci and the
direct involvement of cellular cancer-related genes. In this study we addressed this topic by extending the existing data set
by an additional 47 HPV16 and HPV18 positive cervical carcinoma. We provide supportive evidence for previously defined
integration hotspots and have revealed another cluster of integration sites within the cytogenetic band 3q28. Moreover, in
the vicinity of these hotspots numerous microRNAs (miRNAs) are located and may be influenced by the integrated HPV
DNA. By compiling our data and published reports 9 genes could be identified which were affected by HPV integration at
least twice in independent tumors. In some tumors the viral-cellular fusion transcripts were even identical with respect to
the viral donor and cellular acceptor sites used. However, the exact integration sites are likely to differ since none of the
integration sites analysed thus far have shown more than a few nucleotides of homology between viral and host sequences.
Therefore, DNA recombination involving large stretches of homology at the integration site can be ruled out. It is however
intriguing that by sequence alignment several regions of the HPV16 genome were found to have highly homologous
stretches of up to 50 nucleotides to the aforementioned genes and the integration hotspots. One common region of
homologies with cellular sequences is between the viral gene E5 and L2 (nucleotides positions 4100 to 4240). We speculate
that this and other regions of homology are involved in the integration process. Our observations suggest that targeted
disruption, possibly also of critical cellular genes, by HPV integration remains an issue to be fully resolved.
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Introduction
A persistent infection with high risk human papillomaviruses
(HR-HPV) in particular HPV16 and 18 is recognized as the
highest risk factor for the development of cervical cancer [1]. Most
HR-HPV infections are either latent or permissive. Latent
infections are ill defined but it is assumed that the viral genome
is maintained as an episome in the basal and parabasal cells of the
epithelium without inducing obvious phenotypic alterations in the
host cell. Virus replication in terms of virion production is
confined to terminally differentiated cells of the intermediate and
superficial epithelial layers and results from a switch of a latent to a
permissive phase or directly from an acute infection. Normally
HR-HPV infections are self-limited and resolve within several
months. However, in an estimated 10% of cases a transforming
type of HPV infection evolves. This transformation process is
characterized by the deregulation of viral oncogenes E6 and E7 in
cycling cells which ultimately results in chromosomal instability
and the accumulation of mutations. The underlying mechanisms
for deregulation are manifold. Integration of the HPV genome is a
characteristic step in cervical carcinogenesis and its appearance
correlates with the progression of precancerous lesions (CIN2/3)
to invasive carcinoma [2,3,4,5,6]. However, integration is not
mandatory in this process and was shown to be HPV-type
dependent. Vinokurova and colleagues observed that HPV16, 18
and 45 were substantially more often present in an integrated state
compared with HPV types 31 and 33 [7]. Interestingly the highest
carcinogenic potential is ascribed to HPV16 and HPV18 [8].
The loss of the viral E2 gene is a common consequence of HPV
integration. This event may lead to an elevated expression of the
oncogenes E6 and E7 due to the fact that E2 is no longer able to
repress the expression of the viral oncogenes in trans [9,10].
However, of note is that in a recent analysis of biopsy material no
correlation between the expression levels of viral oncogene
transcripts and the physical state of the viral genome was found
[11]. Since the transcriptionally active viral integration sites thus
far analysed in CIN2/3 or cervical carcinomas represent the end
point of a clonal selection process the most pragmatic interpre-
tation of the data is that integration ensures a constitutive
expression of the viral oncogenes at a level required to maintain
the transformed state of the cell. More recently several investiga-
tors have also focussed on the impact integration may have on the
host genome. A systematic analysis of the genome structure at the
integration locus has revealed frequent genomic structural
alterations at the HPV insertion sites in cervical carcinoma [12].
Two further publications provide evidence for a complete
functional loss of the tumor suppressor genes, ZBTB7C and
CASZ1, respectively. In both cases gene expression is prevented
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heterozygosity [13,14]. Although such constellations are likely to
be rare events it becomes increasingly more evident that HPV
integration does not occur entirely at random. In a previous study
we could show that the majority of viral-cellular fusion transcripts
in cervical carcinomas co-transcribe cellular sequences of known
or predicted genes. Indeed, 17 of 74 (23%) of the integration sites
were located within the cytogenetic bands 4q13.3, 8q24.21,
13q22.1, and 17q21.2, in clusters ranging from 86 to 900 kb. The
integration hotspots 8q24.21 and 13q22.1 are close to adjacent
fragile sites. Of interest is that integration within the MYC locus
on 8q24.21 is strongly correlated with high levels of MYC
expression [15,16,17] implying cis regulatory effects being exerted
by the viral genome.
The phenomenon of non-random integration of HPV DNA is
intriguing and may not just be a question of chromatin accessibility
in transcriptionally active regions or fragile sites which are prone
to double strand breaks [18,19,20]. For a better understanding of
the role and mechanisms of virus integration in cervical
carcinogenesis it is necessary to gather more data for comparative
purposes. Accordingly, we have analysed the viral-cellular fusion
transcripts of 34 HPV16 positive and 13 HPV18 positive cervical
carcinomas. On the basis of this new data the previously defined
hotspots for integration could be confirmed and extended upon.
There is also mounting evidence that numerous genes are affected
more than once by integration.
Results
In 47 of 87 HPV16 or HPV18 positive tumors analysed viral-
cellular fusion transcripts could be amplified. Fusion transcripts
were detected more frequently in HPV18 positive tumors (72%)
than in HPV16 positive tumors (49%). The remaining tumors
contained either only episomal viral genomes or integrated HPV
DNA which is transcriptionally silent. The cellular sequences of
the fusion transcripts were characterized using the NCBI human
megaBlast tool. To identify expressed sequence tags and predicted
genes all additional cellular sequences were analysed using the
UCSC blat database.
Chromosomal Assignment of the Fusion Transcripts
In total, 23 fusion transcripts contained sequences of known
genes and 23 contained sequences of predicted genes and ESTs. In
one case the cellular sequence did not match any database entries.
The viral cellular fusion transcripts could be assigned to all
chromosomes, except for chromosome 11, 14, 16, 18 and 20 and
are summarized in table 1. In a previous study we had already
described that some regions are more frequently affected by
integration than other parts of the genome [21]. For three of these
hotspots we have now found additional integration events: The
regions 8q24.21 and 13q22.1 were affected twice and region
4q13.3 was affected once. Moreover, three fusion transcripts were
mapped to a 600 kb region in the chromosomal cytogenetic band
3q28 and thus represent a new hotspot for HPV integration.
Figure 1 includes the data from Kraus and colleagues and depicts
all five hotspots, their size and the vicinity to related fragile sites
and miRNAs.
Association with Fragile Sites and miRNAs
Of the 47 integration loci identified, 10 (21%) occurred within a
common fragile site (CFS) and 6 (13%) in rare fragile sites.
Moreover, in 15 (32%) cases the integration sites were flanking
fragile sites at a distance of 200 kb up 5 Mb. Another 16
integration sites were not associated with fragile sites. Moreover,
32 integration sites were located within a distance of 3 Mb to
miRNAs (table 1).
Orientation of ORFs within Fusion Tanscripts
Twenty-three of 47 fusion transcripts contained sequences of
known genes. In 12 cases the host gene was orientated in the
direction of viral promoter i.e. both viral and human sequences
were in sense orientation. In almost all of these tumors, the viral
sequence was spliced to a cellular exon sequence (11 of 12 events).
23 fusion transcripts contained predicted gene sequences and 8
were integrated in sense orientation. In 3 cases the orientation
could not be determined because of inconsistency among the
databases used (table 1).
Identical Genes are Affected by Integration in different
Tumors
By compiling the data of this study and published data five
genes and four predicted genes could be identified which were
affected at least twice in independent tumors (Table 2). Four of
these genes are located in the hotspots 3q28 (LEPREL1 and TP63),
8q24.1 (LOC727677) and 13q22.1 (BG182794). The other genes
are located elsewhere in the genome. Whereas the genes
Chr2.3.305.a, LEPREL1, NT_008046.7, and LIPC were affected
twice by integration, TP63 was affected three times, LRP1B,
LOC727677 and BG182794 four times and TMEM49 even six
times.
Moreover, the genes NT_008046.7, LOC727677, BG182794
and TMEM49 are of particular note because at least two tumors
harbour identical viral cellular fusion transcripts with respect to
the viral donor and acceptor splice sites used.
Discussion
HPV integration into the host genome is likely to be a very
frequent event but cannot be readily detected if integration occurs
in a single cell without subsequent clonal selection pressure. In
most cervical cancers there is only one transcriptionally active
HPV integration site. There is evidence that these integration sites
represent early clonal events which have provided a selective
advantage for the expansion of the neoplasm. Because of their
contribution to the carcinogenic process elucidation of these
particular integration events are pertinent for understanding HPV-
induced carcinogenesis.
Viral-cellular fusion transcripts are molecular markers for
transcriptionally active integration sites and can be detected by a
3 `RACE protocol (the APOT assay) which allows PCR amplifica-
tion for subsequent sequence analysis. In this study we have
identified viral-cellular fusion transcripts in 47 cervical carcino-
mas. With one exception the fusion transcripts comprise cellular
sequences of either known or predicted genes. This is in line with
the results of our previous analysis and suggests that integration
occurs mostly in transcriptionally active regions [21]. Moreover, in
agreement with the literature 66% of the integration events were
either within (34%) or adjacent to a fragile site (32%)
[18,19,20,21]. Also integration of HPV DNA near miRNAs is
evident. miRNAs are associated with the regulation of important
processes such as development, proliferation, differentiation and
apoptosis [22] and they are often deregulated in cancer cells
[22,23]. Of the 75 miRNAs in the neighborhood of integration
sites 19 have already been associated with cancer (figure 1). Of
these miR-34a, miR-191, miR-28, miR-944, miR-31, miR-7-2,
miR-9-3, miR-497, miR-195, miR-301a, miR-21, miR-181c,
miR-27a, miR-99a and miR-let7c are expressed in cervical cancer
cells [24,25,26,27,28,29]; whereas miR-34a, miR-21, miR-191,
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PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e39632miR-9-3, miR-181d, miR-23a, miR-24-2, miR-99a and miR-
125b2 are reported to be involved in other tumor entities
[28,30,31,32].
Of note is that for a substantial number of fusion transcripts
(11/47) the viral sequences are spliced in sense orientation to
cellular exons of known genes. Disruption of a gene by HPV
integration, even if this occurs within intron sequences, is likely to
have an impact on gene expression and in rare instances was
shown to have contributed to a complete loss of gene function
[13,14].
An important finding of this study is that it provides further
support for a clustering of HPV integration sites in chromosomal
hotspot regions. Of the 121 tumors analysed (including the data by
Kraus et al., 2008) 22% of the viral-cellular fusion transcripts were
assigned to one of five hotspots (figure 1). The hotspots range in
size from 150 kb to 995 kb and contain up to 8 integration sites.
Moreover, by including further published data 9 genes were found
to be affected at least twice by HPV integration, four of these genes
are located within the hotspots of the cytogenetic bands 3q28,
8q24.21 and 13q22.1 (table 2). This observation is of particular
interest because it suggests that integration is not only associated
with transcriptionally active regions and nearby fragile sites.
Especially since in some tumors even identical viral-cellular fusion
transcripts with respect to viral-cellular splicing were found
(table 2). However, sequencing of the integration sites in case
TMEM49 had shown that the breakpoints of the two respective
tumors are about 17 kb apart. Moreover, both integration sites
showed no homology between the viral and cellular sequences
[14]. DNA recombination involving large stretches of homology at
the integration site can at least be ruled out for TMEM49.
Intriguingly sequence alignment of the genes listed in Table 2 has
revealed several regions with high homology to the HPV16
genome. The most common region of high homology is between
the viral gene E5 and L2 (nucleotides positions 4100 to 4240). Six
of the 9 genes affected at least twice by HPV integration show a
minimum of 80% homology in stretches of up to 34 nucleotides
(Sequences S1). Moreover, each of the 9 genes show further
homologies with other parts of the viral genome. Exemplarily the
positions of the homologous regions of the adjoining genes
LEPREL1 and TP63 with the HPV16 genome are depicted in
figure 2. We speculate that these regions may be involved in the
integration process. It is envisaged that the viral genome is
tethered to chromatin by Brd4 which plays a key role in
chromosomal functional events such as transcription, DNA
replication, repair and recombination [33,34]. The homologous
stretches of DNA may then allow annealing of partially dissociated
strands and thereby contribute to the recombination event.
Sequence homology at the integration site itself need not be a
prerequisite. Beyond this highly speculative scenario it is also
interesting to note that all of the genes involved are cancer
associated genes to varying degrees. If functionally impaired, they
may have played a role in the clonal selection process. For the
predicted genes chr2.3.305.a (N-SCAN), NT_008046.7,
LOC727677 (alias sweeker) and BG182794 no functional data
are available. However, LRP1B belongs to the low density
lipoprotein receptor gene family and plays a role in the process
of receptor-mediated endocytosis. A homozygous loss of LRP1B in
several cervical tumors was found using array-based comparative
genomic hybridization analysis [35]. Also in other tumor entities
like thyroid cancer [36], gastric cancer [37], lung cancer
[38,39,40,41] and oral cancers [42,43] silencing or loss of LRP1B
was observed. In functional terms LRP1B is able to inhibit cell
Figure 1. Chromosomal hotspots for HPV integration. Depicted are integration sites located within the cytogenetic bands 3q28 (A), 4q13.3 (B),
8q24.21 (C), 13q22.1 (D) and 17q21.2 (E). Light blue arrows: genes affected by HPV integration; red arrows: HPV fusion transcripts described in this
work; grey arrows: HPV fusion transcripts described by Kraus et al. 2008; green arrows: fragile site; dark blue arrows: microRNAs.
doi:10.1371/journal.pone.0039632.g001
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e39632migration [44] and its loss may thus be relevant for invasion and
metastasis. The second gene, LEPREL1, encodes a protein
involved in collagen biosynthesis, folding and assembly. Thus far
this gene was not associated with cervical cancer but it was
observed to be silenced breast cancer cell lines and in 26% of
breast cancers analysed [45]. Two further genes are TP63 and
LIPC. TP63, a member of the p53 protein family, is another gene
affected by integration. It acts as a tumor suppressor protein and
aberrant expression was noted for several cancer entities including
cervical cancer [46,47]. LIPC is a cytoplasmic protein mainly
expressed in the liver. It is involved in the lipidprotein metabolism
and catalyzes hydrolysis of phospholipids, mono-, di- and
triglycerides and acyl-CoA thioesters [48]. A direct link to
carcinogenesis is not readily apparent but in a recent study a
complete lack of expression was observed in 18% of cervical
carcinomas. By contrast all normal cervical epithelia, metaplasia
and CIN examined expressed LIPC [14]. The most frequently
affected gene, being disrupted 6 times, is TMEM49 (transmem-
brane protein 49), also known as VMP1 (vacuole membrane
protein 1) located on chromosome 17q23.1. It encodes a plasma
membrane protein which is an essential component of initial cell-
cell contacts and tight junction formations [49]. Reduced
expression of TMEM49 was found for invasive breast cancer cell
lines and in kidney cancer metastasis [49]. TMEM49 also appears
to be particularly prominent in terms of deregulation of nearby
miRNAs. miR21 is located only 676 bp downstream of this gene
and may as a consequence of HPV integration be either up or
down-regulated. Association of this miRNA has been reported for
the caspase cascade [50] and it can target BTG2, a gene with
antiproliferative properties [51]. Thus far miR21 was shown to be
upregulated in multiple cancers such as breast, lung, colon,
pancreas, prostate, stomach, ovary and uterus [28,31,32].
By characterising an increasing number of transcriptionally
active HPV integration sites it has become evident that integration
is not an entirely random event but also involves preferred
chromosomal sites. In individual cases this may impair gene
Table 2. Genes affected by HPV integration at least twice in individual tumors.
Name HPV Pathology Locus Gene
Gene size
(nt) Spliced to
{ Orientation
Detection
method Reference
{
D3918 18 CxCa 2q22.1 LRP1B 1.900.274 n.a. AS Apot Kraus 2008
T654 45 CxCa 2q22.1 LRP1B n.a. AS Apot Kraus 2008
T19 16 CxCa 2q22.1 LRP1B exon 28 S Apot Ziegert 2003
HK9 18 CxCa 2q22.1 LRP1B intron 41
2 n.s. Restriction PCR Ferber 2003
T2882 16 CxCa 2q22.3 chr2.3.305.a 567.027 intron 6–7 S Apot
T3562 18 CxCa 2q22.3 chr2.3.305.a n.a. AS Apot
D3829 45 CxCa 3q28 LEPREL1 164.391 exon 9 S Apot Kraus 2008
T2107
1 16 CxCa 3q28 LEPREL1 exon 15 S Apot
LEPREL1 intron 14–15 S Apot
T4335 16 CxCa 3q28 TP63 265.852 n.a. AS Apot
Clone C5 16 cell line 3q28 TP63
3 intron
2 n.s. Restriction PCR Dall 2008
int4 16 VINX 3q28 TP63 n.s. n.s. Apot Wentzensen 2002
D4045 18 CxCa 8q21.2 NT_008046.7 5.247.020 intron 2 S Apot Kraus 2008
D4056 45 CxCa 8q21.2 NT_008046.7 intron 2 S Apot Kraus 2008
D3464 18 CxCa 8q24.21 LOC727677
4 192.322 exon 6 S Apot Kraus 2008
D3631 45 CxCa 8q24.21 LOC727677
4 n.a. AS Apot Kraus 2008
T5189 16 CxCa 8q24.21 LOC727677 n.a. AS Apot
T6697 18 CxCa 8q24.21 LOC727677 exon 6 S Apot
T3706 16 CxCa 13q22.1 BG182794 133.369 intron 1 S Apot Kraus 2008
D3772 18 CxCa 13q22.1 BG182794 intron 1 S Apot Kraus 2008
D3632 45 CxCa 13q22.1 BG182794 exon 2 S Apot Kraus 2008
T4046 16 CxCa 13q22.1 BG182794 exon 2 S Apot
T182e 16 CxCa 15q22.1 LIPC 136.898 exon 5 S Apot
T1907 16 CxCa 15q22.1 LIPC exon 9 S Apot
T2723 18 CxCa 17q23.1 TMEM49 133.087 exon 12 S Apot
T3231 18 CxCa 17q23.1 TMEM49 exon 12 S Apot
T30 18 CxCa 17q23.1 TMEM49
5 exon 2 n.s. Apot Ziegert 2003
T24 18 CxCa 17q23.1 TMEM49
5 exon 3
2 AS Dips Ziegert 2003
107 16 CxCa 17q23.1 TMEM49
6 exon 12
2 n.s. Restriction PCR Thorland 2003
200229 16 CIN2 17q23.1 TMEM49
5 n.s. n.s. Dips Matovina 2009
{n.s.: not specified; n.a.: not applicable, because fusion transcript is in antisense orientation;
{integration sites without reference result from this work.
1Two fusion transcripts were found in T2107;
2refers to sequenced integration sites;
3TP73L alias TP63;
4sweeker in Kraus 2008 is no longer listed in any database;
5VMP1
alias TMEM49;
6DKFZP566I133 alias TMEM49.
doi:10.1371/journal.pone.0039632.t002
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only speculate on the mechanisms that contribute to this
phenomenon.
Materials and Methods
Clinical Samples
In this study, 69 HPV16 and 18 HPV18 positive biopsies from
cervical carcinoma patients were screened for HPV integration by
the APOT assay. For HPV genotyping a Taqman based multiplex
real-time PCR assay was used [52]. All biopsies were taken from
patients treated at the Department of Gynecology of Friedrich-
Schiller-Universita ¨t, Jena, Germany between 1995 and 2008. All
tumors were histopathologically classified as squamous cell
carcinomas.
Nucleic Acid Isolation
Total RNA was isolated using the NucleoSpin RNA II Kit
(Macherey-Nagel, Du ¨ren, Germany) according to the protocol for
RNA isolation from tissues. Samples were homogenized by the use
of injection needles with a diameter of 0,55 mm. DNA was
removed in all samples by DNase treatment for 15 min (RT).
DNase was supplied with the NucleoSpin RNA II Kit. Total RNA
was eluted in 60 ml RNase-free water and stored at 280uC for
further analysis.
Reverse Transcription
Total RNA (300–500 ng) was reverse-transcribed using 200
units of Superscript II reverse transcriptase (Invitrogen, Carlsbad,
California, USA) and an oligo(dT) primer coupled to a linker
sequence (59-AAG CAG TGG TAT CAA CGC AGA GTA
CT(30)VN-39), referred to as CDS-Primer (Clontech, Heidelberg,
Germany). The reaction was incubated for 70 min at 42uCi na
final volume of 20 ml according to the protocol of the Superscript
II Kit. 40 units of RNaseOUT (Invitrogen, Carlsbad, California,
USA) were added to inhibit RNase activity.
Amplification of Papillomavirus Oncogene Transcript
(APOT) Assay
HPV-derived fusion transcripts were amplified using the APOT
assay [6]. It is based on a 39-rapid amplification of cDNA ends
(RACE) performed in a nested PCR format. HPV E7 primers are
used as forward primers (HPV16: first primer: CGG ACA GAG
CCC ATT ACA AT, second primer: CCT TTT GTT GCA
AGT GTG ACT CTA CG; HPV18: first primer: TAG AAA
GCT CAG CAG ACG ACC, second primer: ACG ACC TTC
GAG CAT TCC AGC AG) and an adapter primer complemen-
tary to the linker sequence in the CDS primer as first reverse
primer and the CDS Primer as second nested primer.
The APOT assay was done as previously described [6] with
slight modifications with regard to the primer used. The reverse
primer for the first PCR comprises the sequence 59-AAG CAG
TGG TAA CAA CGC A-39, the nested PCR primer the sequence
59-AAG CAG TGG TAA CAA CGC AGA GTA CT-39. The
reaction mixture, containing 20 mM Tris-HCl, 50 mM KCl,
1.5 mM MgCl2, 200 mM dNTPs, 250 nM primer each and 0.75
units recombinant Taq Polymerase (Invitrogen, Carlsbad, Cali-
fornia, USA), was subjected to an initial denaturation step for
5 min at 94uC, followed by 30 cycles of denaturation at 94uC for
30 sec, primer annealing for 30 sec and elongation at 72uC for
2 min. For HPV16, annealing temperatures of 61uC and 66uC for
the first and second PCR, respectively, were used; for HPV18,
61uC and 68uC. The reaction was terminated by a final elongation
step at 72uC for 6 min. Two microliters of the first PCR were used
as template for the nested PCR step. Both reactions were
performed in a volume of 25 microliters. The amplification
products were visualized by 1% agarose gel electrophoresis.
Products which differ in their size from the major viral transcript
(E6*1–E7–E1vE4–E5) are indicative for viral-cellular fusion
transcripts. The APOT assay has several limitations. A tumor in
which the integrated HPV genome is transcriptionally silent will
not reveal the characteristic viral-cellular fusion transcript and will
therefore be scored as negative for integration. Moreover, the
assay may not detect viral-cellular fusion transcripts in the
presence of an excess of transcripts derived from episomal HPV
genomes. Finally, a tumor in which the integrated HPV genome
persists in form of a concatemer the viral transcripts may not
comprise cellular sequences and therefore cannot be differentiated
from episome-derived transcripts. Overall the assay underesti-
mates the number of tumors with integrated HPV DNA.
Sequence Analyses
Viral-cellular fusion transcripts were excised from the gel and
extracted using the Zymoclean Gel DNA Recovery Kit (Analy-
tikJena, Jena, Germany). The isolated products were sequenced
(Seqlab, Go ¨ttingen, Germany) and the integration locus was
determined by database alignments using National Centre for
Biotechnology Information (NCBI) human megaBlast tool and the
University of California, Santa Cruz (USCS) genome browser.
Figure 2. Sequence homologies between the HPV16 genome
and the two adjoining genes TP63 and LEPREL1. Three homolo-
gous stretches of up to 50 nucleotides are shown. The number of exact
nucleotide matches is given in brackets (see also Sequences S1). The
DNA loop between the two homologies located on LEPREL1 comprises
102.689 nucleotides; the second loop 269.968 nucleotides. Grey dots
refer to the approximate location of the corresponding viral-cellular
fusion transcripts detected in tumors D3829, T2107 and T4335 (from left
to right).
doi:10.1371/journal.pone.0039632.g002
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For selected samples (n=13) the existence of viral-cellular fusion
transcripts was verified by PCR using viral and cellular integration
specific primers. PCR amplification was performed in a final
volume of 25 microliters containing 20 mM Tris-HCl, 3 mM
MgCl2, 50 mM KCl, 200 mM dNTPs, primer 400 nM each and
1.5U Platinum Taq DNA Polymerase (Invitrogen, Carlsbad,
California, USA). PCR reactions were performed with an initial
denaturation step at 94uC for 10 min, followed by 45 cycles of
denaturation at 94uC for 15 sec, annealing at 58–60uC (depending
on the primer pair used) for 20 sec and elongation at 72uC for
30 sec.
In Silico Analyses
For chromosomal mapping of the viral-cellular fusion tran-
scripts and to relate HPV integration to fragile sites and miRNAs,
the University of California, Santa Cruz (UCSC) genome browser
(hg19) and the Map Viewer (Build 37.3) of the National Centre for
Biotechnology Information (NCBI) were used. All known miRNA
sequences are listed in the miRNA registry ‘‘miRBase’’ (http://
www.mirbase.org/) with 1527 records (release 18) for homo
sapiens.
Investigation of Integration Loci Frequency
To determine the frequency of HPV integration in specific
genes and hotspots, data published by Dall 2008, Ferber 2003,
Kraus 2008, Matovina 2009, Peter 2006, Thorland 2003,
Wentzensen 2002 and 2004 and Ziegert 2003
[3,15,17,19,20,21,53,54,55] were included.
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